Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...

Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...

The New York-based public benefit corporation is advancing three drug candidates for the extremely rare condition.

The trial will test MB-105 in up to 46 patients with relapsed or refractory CD5-positive cutaneous T-cell lymphoma or peripheral T-cell lymphoma.

The €500 million deal is Tessellate's first with a pharmaceutical company and focuses on advancing synthetic lethality therapies ...

Joenja will be the first drug specifically for APDS to be reimbursed within the NHS and is available immediately in England and soon will be in Wales.

NEW YORK – The UK's National Institute for Health and Care Excellence on Tuesday recommended Bristol Myers Squibb's immunotherapy combination Opdivo (nivolumab) and Yervoy (ipilimumab) as a first-line ...

This small branch played a big role in advancing evidence-based genetic testing, and its loss diminishes US leadership in ...

The firms will explore molecular mechanisms and patient responses in cancer to inform development of new therapies.

NEW YORK – Gilead Sciences on Monday said it will share with regulators that its Trop-02-directed antibody-drug conjugate Trodelvy (sacituzumab govitecan-hziy) combined with Merck's checkpoint ...

NEW YORK – AstraZeneca on Monday said it will share interim data with regulatory authorities from the Phase III DESTINY-Breast09 trial, in which patients with HER2-positive metastatic breast cancer on ...